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Oral Mucositis and Stomatitis Associated with Conventional and Targeted 
Anticancer Therapy 
Abstract 
Oral mucositis and stomatitis are characterized by pain, inflammation, and redness in the oral cavity. In 
the case of mucositis, ulceration also occurs. Despite being understudied, these symptoms are some of 
the most troubling, and yet common, adverse effects associated with cancer treatment. The incidence of 
these toxicities is highly variable depending on treatment-related and patient-related risk factors. 
However, most cancer treatment regimens carry some risk of this toxicity. The presence of mucositis or 
stomatitis can result in a significant decrease in the patient?s quality of life due to severe pain and the 
inability to eat or drink. These toxicities can also negatively affect the overall outcome of cancer 
treatment, leading to dose reductions and delays in treatment. Although the mechanism is not yet 
understood, the rapid increase in the number of targeted anticancer therapies available on the market has 
increased the number of patients who experience oral toxicities. The toxicities caused by targeted agents 
are less severe than those caused by conventional anticancer agents, but due to prolonged dosing 
schedules, they can still lead to significant declines in quality of life. The pathobiology of oral mucositis is 
a complex five phase process. It involves injury, activation of enzymes and transcription factors, 
upregulation of cytokine genes, inflammation/damage to tissue, and healing. These processes not only 
involve cells in the oral mucosa, but also the surrounding fibroblasts and connective tissue cells. A better 
understanding of the mechanisms behind oral mucositis and stomatitis will facilitate the development of 
effective prediction, prevention, and treatment strategies. 
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Introduction
It is indisputable that the effective treatment of malignancies is 
often limited by the harm inflicted on normal, healthy cells [1]. Given 
their high rate of turnover, mucosal cells in the oral cavity are highly 
susceptible to the toxic effects of cancer treatment [2]. Toxicities of 
the oral cavity, which include mucositis and stomatitis, are some of 
the most significant and unavoidable toxicities associated with cancer 
treatment [3]. Advances in the ability of anticancer treatment to 
damage and kill cancer cells has also led to changes in the incidence, 
nature, and severity of oral complications [3]. Cytotoxic chemotherapy 
has long been associated with a high risk of oral toxicity. However, 
the risk associated with the newer targeted agents is only begun to be 
realized. Despite being underreported and often under recognized, oral 
toxicities have a tremendous impact on the cancer patient and on the 
resources of the healthcare system. For example, oral toxicities are a 
common cause of dose delays and interruptions of cancer therapy [4]. 
Unfortunately, the currently available treatments for oral toxicities are 
primarily palliative and in many cases, only marginally effective [5-
7]. The lack of effective treatments and prevention strategies may be 
attributed to the fact that research on oral toxicities has lagged behind 
research on other chemotherapy and radiation-related toxicities such as 
febrile neutropenia and nausea and vomiting [4].
Mucositis and Stomatitis
The damage inflicted upon the oral cavity by various modalities 
of cancer treatment can result in a variety of conditions including 
oral mucositis and stomatitis. Clinically, the terms mucositis and 
stomatitis are often used interchangeably, but they do not have identical 
pathologies [2].
Mucositis is the term describing the lesions caused by anticancer 
agents. It can occur to any mucosal cells, but most commonly occurs in 
the cells of the oral cavity and small intestine[5]. Oral mucositis caused 
by cytotoxic chemotherapy is characterized by painful inflammation, 
erythema, swelling, and ulcerations of the oral mucosa in the oral 
cavity, oropharynx, and hypopharynx [8,9]. Oral mucositis varies 
in intensity from a grade 1 to a grade 4. Grade 1 is characterized by 
redness and soreness and grade 4 prevents the patient from ingesting 
anything orally (Table 1) [10].
Stomatitis refers to inflammation that occurs in any tissue in the oral 
cavity [9]. Therefore, stomatitis includes a broad range of conditions, 
including oral mucositis. A majority of the research performed to date 
has specifically focused on oral mucositis. However, the increasing use 
of targeted anticancer agents (e.g. mammalian target of rapamycin 
(mTOR) inhibitors, inhibitors of Epidermal Growth Factor Receptor 
(EGFR) signaling, and tyrosine kinase inhibitors) has brought forth the 
need to carefully distinguish between the pathology and pathogenesis 
of mucositis and stomatitis. 
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Epidemiology of Oral Mucositis
The incidence and severity of mucositis is highly variable and is 
dependent on treatment-related and patient-related risk factors [11] 
(Table 2). Currently, treatment-related risk factors are more important 
to consider than patient-related factors, and should be assessed 
before treatment initiation [4]. Treatment-related risk factors include 
type, dose, schedule of chemotherapy, route of administration, and 
concomitant use of chemotherapy and radiation [9,12]. Patients who 
receive standard-dose chemotherapy has an estimated 40% risk of 
all-grade mucositis [13] and the risk of mucositis approaches 100% 
in patients with head and neck cancer who receive both intensive 
chemotherapy and radiation [4,14]. The overall risk of developing 
mucositis and the severity of mucositis positively correlate with the 
number of chemotherapy cycles due to increased exposure and the 
cumulative damage caused by anticancer agents [3,4].
The reported incidence of mucositis is striking. However, it is 
likely what the true incidence of mucositis in clinical practice is much 
higher. Currently available knowledge on oral mucositis is derived 
from clinical trials. Unfortunately, relatively few clinical trials have 
focused on mucositis as a specific outcome and clinical trials often 
do not include the full range of patients (e.g. elderly patients, patients 
with comorbidities, non-adherent patients) [4]. Additionally, mucositis 
often emerges between treatment cycles when clinical monitoring is 
sporadic [15].
Although it is difficult to predict whether a patient will develop 
mucositis solely based on the class of drug dispensed [2], there are 
several drugs that are associated with an increased propensity to damage 
the oral mucosa. These drugs include methotrexate, doxorubicin, 
5-fluorouracil, busulfan, bleomycin, cisplatin, carboplatin, mTOR 
inhibitors, inhibitors of EGFR signaling, and selected tyrosine kinase 
inhibitors [2,4,8,16-19].
Most research has focused on treatment-related risk factors, given 
the variable response of individual patients to the same treatment 
regimen. However, patient-related risk factors also play an important 
role in oral toxicity risk [4]. Currently, data is inconclusive pertaining 
to the influence of age, gender, body mass index, and nutritional status 
on chemotherapy-induced mucositis [4,20]. However, the impact of 
genetic factors has become unmistakable. Importantly, differences in 
the expression of genes associated with the pathogenesis of mucositis 
are common [9]. For example, polymorphisms in the tumor necrosis 
factor genes have been shown to increase the risk of toxic lesions [21]. 
Additionally, although relatively rare, deficiencies in drug metabolizing 
enzymes due to genetic polymorphisms have been associated with an 
increased risk of methotrexate-induced and 5-fluorouracil-induced 
toxicity [22-24].
Impact on Patients
As reported by patients, mucositis is one of the most significant 
adverse symptoms of cancer therapy [25,26]. Resources that are needed 
to manage the acute effects of mucositis and its impact on the patient 
include, but are not limited to: total parental nutrition, increased use 
of antifungals and opioid analgesics, increased emergency department 
visits, and increased hospitalizations [4,27, 28]. The substantial pain 
and ulceration can lead to a decline in oral health, nutritional status, 
quality of life, and in severe cases, even death [27,29-31]. The pain 
associated with mucositis can persist after treatment is complete and 
its management may require parenteral opioid analgesics [32,33]. 
Unfortunately, opioid analgesics are not always effective in managing 
the pain and are associated with aversive side effects such as constipation 
and a decrease in alertness [9,25,27]. The pain can also interfere with the 
patient’s ability to eat and drink which can lead to weight loss in already 
frail patients and required initiation of total parenteral nutrition [26].
The ulcerations in mucositis can create a portal of entry for 
pathogens in a patient that may already be immunocompromised due 
to myelosuppression [4]. In severe cases, this can lead to life-threatening 
systemic infections [34,35]. Research has shown that infection 
occurs in 36% of solid tumor patients receiving myelosuppressive 
therapy. However, in patients who experience mucositis due to 
myelosuppressive therapy, the occurrence of infection increases to 73% 
[15]. Unfortunately, these infections may be hard to prevent and predict 
because there are no specific criteria for determining risk of infection 
during myelosuppression [2].
Mucositis can be considered a dose-limiting toxicity. A reduction 
or delay in treatment may be warranted given complications associated 
with pain, infection, and inability to eat. As reviewed by Elting et al. 
[28], mucositis can lead to a dose reduction of chemotherapy in 23%-
28% of cycles. These dose reductions are a major source of concern 
because they can directly diminish cure rates and patient survival [5].
Pathobiology of Mucositis
The emergence of oral mucositis after intensive chemotherapy 
occurs approximately two weeks after chemotherapy initiation [36], 
which corresponds to the estimated mitotic rate of oral epithelium of 
9 to 16 days [37]. It was previously thought that mucosal toxicity was 
simply due to the direct toxicity of chemotherapy agents on mucosal 
cells [38]. However, research has determined that the development of 
mucositis involves not only the mucosal epithelium, but the submucosa 
and the extracellular matrix [39]. The pathobiology follows a discrete five 
phase process that includes: 1. Initiation, 2. Signaling, 3. Amplification, 
4. Ulceration, and 5. Healing [6,39] (Table 3). An important implication 
of this model is that it identifies a variety of potential therapeutic 
Treatment-related Patient-related
• Type of medication • Type of malignancy
• Dose • Age
• Schedule of medication (e.g. 
number of cycles) • Poor oral health and hygiene
•  Route of administration • Salivary gland dysfunction
• Concomitant radiation therapy • Body mass index
• Dose and field of radiation • Gender
• Genetic polymorphisms in drug 
metabolizing enzymes[22]and TNF-α [21]
• Co-morbid disease states (e.g. psoriasis, 
Addison’s disease, diabetes) [6]
Table 2: Risk factors for oral mucositis adapted from [9,20].
Phase I – 
Initiation
Exposure to chemotherapy or radiation causes generation of 
reactive oxygen species (ROS) and lipid peroxidation. This results 
in DNA damage and cellular apoptosis
Phase II – 
Signaling
ROS cause further damage and stimulate the expression of 
NF-κB. NF-κB expression leads to increased production of 
proinflammatory cytokines (TNF-α, IL-1β, IL-6)
Phase III – 
Amplification
Release of proinflammatory cytokines leads to prolonged 
tissue injury, apoptosis, vascular permeability, and activation of 
cyclooxygenase-2.
Phase IV – 
Ulceration
Ulceration occurs, providing a portal for the entry for colonization 
of microorganisms. Bacteria cause activation of macrophages and 
further production of proinflammatory cytokines
Phase V – 
Healing
Signals from submucosa promote epithelial proliferation and 
differentiation
Table 3: The phases of oral mucositis adapted from [6,39].
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targets (e.g. sequesters of free radicals, inhibitors of pro-inflammatory 
cytokines) that could hinder or reverse the development of mucositis.
Another interesting aspect of the model is that it demonstrates that 
microorganisms are a coincident condition and not a direct cause of 
mucositis [6]. In a hamster model of mucositis, the development of 
lesions preceded increases in bacterial colonization [6]. Even though 
microorganisms may not directly cause mucositis, it is important to 
note that the presence of infection can often complicate the diagnosis 
and management of oral mucositis [40].
Oral Toxicity Caused by Targeted Anticancer Therapy
The use of targeted agents in the treatment of cancer has recently 
exploded and has had a significant positive impact on patient quality 
of life and survival rates [1]. Since 2012, 14 agents have been approved 
by the U.S. Food and Drug Administration [41]. These agents influence 
or inhibit the signaling of many cellular targets including mTOR, 
EGFR, vascular endothelial growth factor, hedgehog, human epidermal 
growth factor receptor 2, and several tyrosine kinases. This explosion 
of targeted agents represents the products of the extensive research that 
has occurred in the field of cancer cell biology. However, the presence 
and function of some of these targets in normal cells is just beginning 
to be understood. Unfortunately therefore, targeted anticancer therapy 
can also cause significant toxicity to non-cancer cells.
Mucositis is one of the most commonly reported toxicities of mTOR 
inhibitors [42,43], and in some studies, it was the dose-limiting toxicity 
[44]. Oral toxicities with other targeted agents, such as the kinase 
inhibitors and monoclonal antibodies are less common. Yet studies have 
shown a significant incidence of all-grade mucositis with bevacizumab, 
erlotinib, sorafenib, and sunitinib [15,43]. The incidence of oral toxicity 
associated with targeted agents has been shown to increase as the dose 
increases [45]. However, unlike with the conventional anticancer agents, 
subsequent cycles of targeted agent therapy can lead to a decrease in the 
frequency and severity of oral toxicity [45].
The clinical presentation of targeted agent-induced oral mucositis 
is quite different from radiation or chemotherapy-induced mucositis. 
Typically, it has a rapid onset (within 5 days) and is of mild to moderate 
severity (grade 1-2). The lesions are round and have similar appearance 
to aphthous stomatitis (canker sores) [12,46]. Another distinguishing 
feature of targeted therapy-induced oral toxicity is that the lesions are 
more likely to resolve spontaneously even when treatment is continued 
[42]. Given these differences, the toxicities seen with targeted agents 
may be better classified as stomatitis, rather than oral mucositis 
[12,40,47]. 
Although the severity of targeted agent-induced oral toxicity is less 
severe than that caused by conventional chemotherapy, it may still be 
dose-limiting [12,17,19]. Treatment with targeted agents is often long-
term and may continue until the cancer has progressed or unacceptable 
toxicity occurs. Because many of the targeted agents are taken orally 
and are self-administered, the negative impact of targeted therapy-
induced oral toxicities on patient adherence and treatment outcomes 
is significant [17,48]. 
The exact mechanism of how targeted agents produce oral toxicities 
is likely different than the pathways described for conventional 
chemotherapy agents. Recent research done in a clinically relevant 
rat model of tyrosine kinase inhibitor-induced diarrhea has identified 
that unlike with conventional chemotherapy agents, tyrosine kinase 
inhibitors do not cause direct damage to mucosal cells [49]. However, 
apart from that, the targeted agent-induced mechanism is not well-
understood. This may be due in part because targeted agents are often 
given in conjunction or after conventional anticancer therapies have 
been given. Therefore, the toxicities of targeted agents can combine 
with or accentuate the toxicities of conventional chemotherapy and it 
may be difficult to distinguish toxicities solely caused by the targeted 
agent. 
Future Directions 
Recent years have seen an increase in the amount and the momentum 
surrounding mucositis research in both clinics and in laboratories. 
Unfortunately, anticancer agents are not currently classified based on 
their oral mucositis risk [4]. Therefore, strategies for prevention and 
treatment are still limited and the majority of currently available studies 
have significant weaknesses [9]. For example, there are few studies that 
focus on chronic complications and survivorship issues [8]. However, 
as cancer survivor rates increase, it becomes important to understand 
the impact of mucositis on the long-term oral health and well-being of 
the patient [3]. Additionally, given the impact that oral toxicities have 
on daily functioning, there is a need for research to focus not only on 
the incidence of oral mucositis and stomatitis, but also on the severity 
and duration. In order to accomplish this, studies would likely need 
to increase monitoring between treatment cycles and also incorporate 
patient-reported symptoms with clinical diagnostic tools [15]. 
The discovery of the complex pathobiology of mucositis has 
undeniably created several potential avenues for drug development and 
research [6]. However, given the complexity of most cancer treatment 
regimens, it will be challenging to manage the toxicities of simultaneous 
multiple agents, some of which have an unknown mechanism, 
without jeopardizing the ultimate goal of destroying cancer cells [50]. 
For example, it is possible that the desired treatment effect and the 
undesired toxicity are inseparable and that attenuating toxicity will also 
lead to reductions in efficacy [51]. 
Conclusion
As Sonis states, mucositis is toxicity that “largely defies effective 
intervention” [12,50]. Now that febrile neutropenia and chemotherapy-
induced nausea and vomiting are managed with various pharmacologic 
agents, mucositis has become one of the most troubling dose-limiting 
toxicities for patients. However, given the tremendous impact that these 
oral toxicities have on the patient and the healthcare system, urgent 
studies are needed to develop effective strategies for prevention and 
treatment.
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